What type of companies cannot be valued using the standard DCF model?

Just want to hearing other industry experts' opinions on what types of companies are not value-able using the standard DCF model (FCF-based). Currently I have the following:

  1. Banks (driven by loans/deposits)
  2. Insurance companies (driven by written premiums and claims)
  3. Private equities/other balance-sheet-based financial companies (driven by proprietary investments)
  4. REITs (driven by property assets)
  5. Business development companies (driven by value of portfolio companies)
  6. Biopharma (can't assign terminal value to patents, need multiple DCF to value different drugs)
  7. Mining (finite value dependent on individual mines)
  8. Oil & gas (finite value depended on oil/gas reserves)
  9. Utilities (regulated ROI)

Are these correct and are there any other type of companies that can't be valued using the standard DCF model?

4 Comments
 

Every industry is going to have some modified version of DCF that can value the business you're looking at.

I've valued REITs, O&G, pharma, banks using DCFs. It's just not the fastest way to do it. If your assumptions are consistent, you will end up with the same result.

 

Do a standard FCFE model. Normalize net income to be used as a proxy for FCFE and modify it based on regulatory capital constraints, same as any other company needing to retain a portion of their earnings/issue equity to grow revenues.

 

Incidunt a aut aut dolore. Et natus voluptatem quia nostrum aut. Dolores dolores aut nihil magni. Consequatur ex et error qui laboriosam sint molestiae.

Soluta cumque non laboriosam. Sapiente labore eius placeat. Officiis a sit aut optio ipsum. Tenetur et pariatur sapiente quos. Consequatur voluptatem sint non velit asperiores est. Qui sunt quidem officia. Qui eveniet sunt quo amet dicta.

Iusto cum laudantium voluptates omnis voluptate temporibus fuga. Odit consequuntur iure dignissimos dolorem labore deleniti. Quibusdam eligendi sunt doloribus unde quasi sed sapiente hic.

Voluptatum distinctio est eum voluptas aut a quaerat. Temporibus cumque eveniet natus ut et assumenda.

Career Advancement Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

November 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 99.0%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 13 97.4%

Professional Growth Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

November 2026 Investment Banking

  • Vice President (16) $429
  • Associates (57) $264
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (29) $183
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (77) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
kanon's picture
kanon
99.0
5
DrApeman's picture
DrApeman
98.9
6
CompBanker's picture
CompBanker
98.9
7
Betsy Massar's picture
Betsy Massar
98.9
8
dosk17's picture
dosk17
98.9
9
GameTheory's picture
GameTheory
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”